Gene therapy back with FDA as Ferring, Blackstone reshape deal

More than two years after a regulatory hold-up, Ferring has resubmitted its gene therapy for bladder cancer to FDA and restructured a deal in which Blackstone had invested in the program.

In a statement to BioCentury, the partners said Ferring Pharmaceuticals A/S has assumed control of FerGene Inc., the entity it set up in 2019 with Blackstone Life Sciences with the goal of commercializing nadofaragene firadenovec to treat patients with high grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer (NMIBC)...